News

On Monday’s call, Hims & Hers CFO Oluyemi Okupe said that personalized semaglutide dosages will supplement the company’s core offerings. The company announced in November that it plans to ...
Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide ... The chart below shows that this metric ...